The FDA has approved Scholar Rock’s ISEMBYLD for spinal muscular atrophy in adults and children ages 2 and older who are currently receiving a survival motor neuron 2-targeted treatment. ISEMBYLD is the first muscle-targeted treatment approved for children and adults with SMA who are receiving an SMN2-targeted treatment.
The approval was based on results from the Phase 3 SAPPHIRE study, according to a Sept. 11 press release. Patients receiving the recommended 10 milligram dose showed a 2.2-point improvement in motor function compared with placebo at one year.
The study also found 34.2% of ISEMBYLD-treated patients had a 3-point or greater increase in motor function compared with 13.5% of placebo-treated patients.
The safety database includes more than 500 individuals across apitegromab clinical studies globally, some of whom have been on treatment for more than seven years. Fractures occurred in 9% of patients treated with ISEMBYLD 10 milligram compared with 2% of those who received placebo.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
